KR102545365B1 - Fermentation composition of mountain-cultivated ginseng having increased ginsenoside Rd, Rc and Protopanaxadiol by using Tricholoma matsutake mycelium and preparation method thereof - Google Patents
Fermentation composition of mountain-cultivated ginseng having increased ginsenoside Rd, Rc and Protopanaxadiol by using Tricholoma matsutake mycelium and preparation method thereof Download PDFInfo
- Publication number
- KR102545365B1 KR102545365B1 KR1020200135163A KR20200135163A KR102545365B1 KR 102545365 B1 KR102545365 B1 KR 102545365B1 KR 1020200135163 A KR1020200135163 A KR 1020200135163A KR 20200135163 A KR20200135163 A KR 20200135163A KR 102545365 B1 KR102545365 B1 KR 102545365B1
- Authority
- KR
- South Korea
- Prior art keywords
- protopanaxadiol
- present
- wild ginseng
- fermented
- ginsenoside
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 61
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 60
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 60
- 241000121220 Tricholoma matsutake Species 0.000 title claims abstract description 45
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 title claims abstract description 32
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 title claims abstract description 31
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 241000208340 Araliaceae Species 0.000 title claims abstract 5
- 238000000855 fermentation Methods 0.000 title claims description 29
- 230000004151 fermentation Effects 0.000 title claims description 28
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 title claims description 11
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 title claims description 10
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 title claims description 10
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 title claims description 10
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 title claims description 8
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 title claims description 7
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 title claims description 7
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 43
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 38
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 28
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 28
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 28
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000005642 Oleic acid Substances 0.000 claims abstract description 28
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 28
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 28
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 20
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 20
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 20
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims abstract description 8
- 235000021329 brown rice Nutrition 0.000 claims description 18
- 229940089161 ginsenoside Drugs 0.000 claims description 14
- 244000068988 Glycine max Species 0.000 claims description 12
- 235000010469 Glycine max Nutrition 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000010025 steaming Methods 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 8
- 240000004371 Panax ginseng Species 0.000 description 56
- 230000000052 comparative effect Effects 0.000 description 40
- 239000000243 solution Substances 0.000 description 29
- 239000000523 sample Substances 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 19
- 238000002835 absorbance Methods 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000002292 Radical scavenging effect Effects 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 230000003078 antioxidant effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 8
- 102000019280 Pancreatic lipases Human genes 0.000 description 8
- 108050006759 Pancreatic lipases Proteins 0.000 description 8
- 108010028144 alpha-Glucosidases Proteins 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 229940116369 pancreatic lipase Drugs 0.000 description 8
- 235000013824 polyphenols Nutrition 0.000 description 8
- 244000046052 Phaseolus vulgaris Species 0.000 description 7
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 7
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 7
- 229930003935 flavonoid Natural products 0.000 description 7
- 150000002215 flavonoids Chemical class 0.000 description 7
- 235000017173 flavonoids Nutrition 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000001965 potato dextrose agar Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004186 food analysis Methods 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- -1 glycoside compounds Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/10—General methods of cooking foods, e.g. by roasting or frying
- A23L5/13—General methods of cooking foods, e.g. by roasting or frying using water or steam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Abstract
본 발명에서는 산양삼을 송이버섯균사체로 발효하여 제조한 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산 및 리놀레산이 현저히 증진된 발효조성물 및 그 제조방법이 개시된다.
본 발명에 따른 산양삼 송이버섯균사체 발효조성물은 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산, 및 리놀레산이 고함량으로 함유되어 기능성식품 및 화장품의 소재로 사용될 수 있다.In the present invention, a fermented composition with significantly enhanced ginsenosides Rd and Rc, protopanaxadiol, oleic acid and linoleic acid prepared by fermenting wild ginseng with matsutake mushroom mycelium and a method for producing the same are disclosed.
Wild ginseng matsutake mushroom mycelium fermented composition according to the present invention contains a high content of ginsenosides Rd, Rc and protopanaxadiol, oleic acid, and linoleic acid, so it can be used as a material for functional foods and cosmetics.
Description
본 발명은 진세노사이드 Rd, Rc 및 프로토파낙사디올이 강화된 산양삼의 송이버섯균사체 발효조성물 및 그 제조방법에 관한 것으로, 더 상세하게는 산양삼을 송이버섯균사체로 발효하여 제조한 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산 및 리놀레산이 현저히 증진된 발효조성물 및 그 제조방법에 관한 것이다.The present invention relates to a fermented composition of wild ginseng matsutake mushroom mycelium enriched with ginsenosides Rd, Rc and protopanaxadiol and a method for producing the same, and more particularly, to a ginsenoside Rd prepared by fermenting wild ginseng with matsutake mushroom mycelium. , Rc and protopanaxadiol, oleic acid and linoleic acid are remarkably enhanced, and a method for preparing the same.
삼(Ginseng)은 재배환경에 따른 인위적인 성장과 자연적인 성장의 차이와 형태학적 차이 등에 따라 인삼(人蔘), 산삼(山蔘), 또는 산양삼(山羊蔘)으로 구분한다. 특히 산양삼은 오가피과에 속하며 다년생 초목인 인삼(Panax ginseng)이 산간의 삼림하의 야생상태에서 자연적으로 성장한 산삼의 씨앗이나 유삼을 인위적으로 산에서 재배한 것을 말하며 이들을 산양삼이라 한다. 인삼의 경우에는 대부분 노두(머리 부분)가 3-7개 정도이나 산양삼은 연령에 따라 그 이상인 것이 많으며 인삼의 뿌리는 굵고 짧으나 산양삼은 길고 가늘다. Ginseng is classified into ginseng, wild ginseng, or wild ginseng according to the difference between artificial growth and natural growth according to the cultivation environment and morphological differences. In particular, Sanyangsam belongs to the Ogapicaceae family, and Panax ginseng , a perennial plant, refers to wild ginseng seeds or young ginseng grown naturally in the wild under mountainous forests, which are artificially cultivated in the mountains, and they are called Sanyangsam. In the case of ginseng, most of them have 3-7 outcrops (head part), but sanyangsam has more than that depending on age, and the root of ginseng is thick and short, but sanyangsam is long and thin.
사포닌은 식물계에 널리 분포하고 있는 트리텔펜과 스테로이드계 배당체 화합물의 총칭이다. 삼의 사포닌인 진세노사이드(ginsenoside)를 함유한 산양삼은 한약처방전에서 천연 자연 산삼 다음으로 효능을 높이 평가하고 있다. 또한 재배인삼과 비교시 진세노사이드 함량이 높다고 보고되어져 있으며 재배된 인삼보다 효능 또한 뛰어남이 알려져 있다. 그러나 알려진 산양삼 관련 가공품들은 진세노사이드 함유량이 기준치 미달이거나 약리작용이 있은 희귀 진세노사이드 Rd, Rc는 거의 함유되어 있지 않은 실정이다. Saponin is a generic term for triterpene and steroid-based glycoside compounds widely distributed in the plant kingdom. Wild ginseng, which contains ginsenoside, a saponin of hemp, is highly evaluated for efficacy next to natural wild ginseng in herbal medicine prescriptions. In addition, it has been reported that the ginsenoside content is higher than that of cultivated ginseng, and it is known that the efficacy is superior to that of cultivated ginseng. However, known wild ginseng-related processed products do not contain rare ginsenosides Rd and Rc, or the content of ginsenosides is below the standard level or has pharmacological action.
진세노사이드 Rd는 면역력증강, 뇌인지기능향상, 신경 퇴행성 뇌질환 개선, 주름개선 기능이 보고되어 있고, 진세노사이드 Rc는 항당뇨 효능, 항염증 효능이 알려져 있고, 진세노사이드 프로토파낙사디올은 진정작용, 면역증강, 해독작용, 항암작용, 항산화 효능이 알려져 있다 (등록특허 10-1198266호). Ginsenoside Rd has been reported to enhance immunity, improve brain cognitive function, improve neurodegenerative brain diseases, and improve wrinkles. Ginsenoside Rc is known to have antidiabetic and anti-inflammatory effects, and ginsenoside protopanaxadiol It is known for its sedative, immune enhancing, detoxifying, anticancer, and antioxidant effects (Patent No. 10-1198266).
올레산(oleic acid)은 단일불포화 오메가-9 지방산으로 분류되며, 리놀레산(linoleic acid)은 다불포화 오메가-6 지방산이며, 음식물을 통해 섭취해야 하는 사람의 필수 지방산들 중 하나이다. 올레산과 리놀레산은 혈중 콜레스테롤 농도를 낮추고 저밀도 콜레스테롤을 감소시키며, 혈압을 낮추고, 심장 질환 예방에 효과가 있으며, 피부보습 효능도 보고되어 있다. Oleic acid is classified as a monounsaturated omega-9 fatty acid, and linoleic acid is a polyunsaturated omega-6 fatty acid and is one of the essential fatty acids for humans that must be consumed through food. Oleic acid and linoleic acid are reported to lower blood cholesterol levels, reduce low-density cholesterol, lower blood pressure, prevent heart disease, and have skin moisturizing effects.
그러나 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산 및 리놀레산이 현저히 증진된 발효조성물은 개발된 바 없다.However, a fermented composition in which ginsenosides Rd and Rc, protopanaxadiol, oleic acid and linoleic acid are significantly enhanced has not been developed.
이에 본 발명자들은 종래 기술의 요구에 부응하기 위한 연구를 지속한 결과, 산양삼을 송이버섯균사체로 발효한 경우, 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산 및 리놀레산이 현저히 증진됨을 확인하고 본 발명을 완성하게 되었다.Accordingly, as a result of continuing research to meet the needs of the prior art, the inventors of the present invention confirmed that when wild ginseng was fermented with matsutake mushroom mycelium, ginsenosides Rd, Rc, protopanaxadiol, oleic acid and linoleic acid were remarkably enhanced. invention was completed.
따라서 본 발명의 목적은 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산 및 리놀레산이 강화된 산양삼의 송이버섯균사체 발효조성물을 제공하는 것이다.Therefore, an object of the present invention is to provide a fermented composition of matsutake mushroom mycelium of wild ginseng, enriched with ginsenosides Rd, Rc, protopanaxadiol, oleic acid and linoleic acid.
본 발명의 또 다른 목적은 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산 및 리놀레산이 강화된 산양삼의 송이버섯균사체 발효조성물의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for producing a fermented composition of matsutake mushroom mycelium of wild ginseng, which is enriched with ginsenosides Rd, Rc, protopanaxadiol, oleic acid and linoleic acid.
본 발명의 또 다른 목적은 본 발명의 산양삼의 송이버섯균사체 발효조성물을 포함하는 기능성식품을 제공하는 것이다.Another object of the present invention is to provide a functional food containing the fermented matsutake mushroom mycelium composition of wild ginseng of the present invention.
본 발명의 또 다른 목적은 본 발명의 산양삼의 송이버섯균사체 발효조성물을 포함하는 화장품을 제공하는 것이다.Another object of the present invention is to provide a cosmetic product containing the fermented matsutake mushroom mycelium composition of wild ginseng of the present invention.
상기 목적을 달성하기 위하여, 본 발명은 산양삼, 콩 및 현미의 혼합물을 송이버섯균사체로 발효하여 제조된 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산 및 리놀레산이 증진된 산양삼의 송이버섯균사체 발효조성물을 제공한다.In order to achieve the above object, the present invention ferments the matsutake mushroom mycelium of wild ginseng with enhanced ginsenosides Rd, Rc and protopanaxadiol, oleic acid and linoleic acid prepared by fermenting a mixture of wild ginseng, soybeans and brown rice into matsutake mushroom mycelium. composition is provided.
본 발명에서 산양삼은 「산지관리법」제2조 제1호에서 정의하고 있는 산지에서 차광막 등 인공시설을 설치하지 아니하고 생산되는 삼을 칭하는 것으로, 바람직하게는 3년근에서 5년근 사이 재배된 것을 사용한다. In the present invention, wild ginseng refers to ginseng produced without installing artificial facilities such as shading in the production area defined in
본 발명의 혼합물에서 산양삼은 90~94 중량%, 콩은 3~5 중량%, 현미는 3~5 중량%로 포함되는 것이 바람직하고, 가장 바람직하게는 산양삼 90 중량%, 콩 5 중량%, 현미 5중량%가 포함된다. In the mixture of the present invention, it is preferable to include 90 to 94% by weight of wild ginseng, 3 to 5% by weight of soybeans, and 3 to 5% by weight of brown rice, most preferably 90% by weight of wild ginseng, 5% by weight of soybeans, and brown rice. 5% by weight.
산양삼의 중량%가 상기 범위를 벗어나면, 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산 및 리놀레산의 함량이 떨어지며, 콩 및 현미의 중량%가 상기 범위를 벗어나면 송이버섯균사체의 균사 성장이 충분하지 않을 수 있다. 송이버섯균사체의 성장 정도와 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산 및 리놀레산의 함량을 모두 고려할 때 산양삼 : 콩 : 현미의 중량비는 90 : 5 : 5인 것이 가장 바람직하다. When the weight % of wild ginseng is out of the above range, the content of ginsenosides Rd, Rc and protopanaxadiol, oleic acid and linoleic acid falls, and when the weight % of beans and brown rice is outside the above range, mycelial growth of matsutake mushroom mycelium may not be enough. Considering the degree of growth of matsutake mushroom mycelium and the contents of ginsenosides Rd, Rc, protopanaxadiol, oleic acid and linoleic acid, the weight ratio of wild ginseng: soybean: brown rice is most preferably 90: 5: 5.
본 발명에서 콩과 현미는 주로 송이버섯균사체가 생육에 필요한 질소원과 탄소원의 역할을 하면서도 송이버섯균사체의 발효(물질전환작용)를 증진시키는 기능도 한다. In the present invention, beans and brown rice mainly serve as nitrogen and carbon sources necessary for the growth of matsutake mushroom mycelium, but also function to enhance fermentation (material conversion action) of matsutake mushroom mycelium.
본 발명에서 산양삼은 세척한 후 건조하고 세절하여 사용하는 것이 바람직하며, 콩과 현미는 세척하고 물기를 제거한 것을 사용한다. In the present invention, wild ginseng is preferably used after washing, drying, and cutting, and beans and brown rice are used after washing and drying.
본 발명에서 '송이버섯균사체'는 송이버섯의 균사체를 의미한다. 송이버섯균사체는 수확시기와 상관없이 언제든지 이용가능하고 자실체와 유사한 항암, 체지방 감소, 혈중 콜레스테롤 저하 및 면역증가 효과 등의 효능을 가지며, 특히 균사체 성장 중에 β-글루코시다아제를 포함한 섬유소 분해효소, 단백질 분해효소, 지방질 분해효소 등의 다양한 가수분해효소를 생성한다.In the present invention, 'matsutake mushroom mycelium' means the mycelium of pine mushrooms. Matsutake mushroom mycelium is available at any time regardless of harvest time and has effects such as anti-cancer, body fat reduction, blood cholesterol lowering and immunity enhancement effects similar to fruiting bodies. It produces various hydrolytic enzymes such as lyase and lipolytic enzyme.
본 발명에서 '발효'는 송이버섯균사체를 종균으로 사용하여 발효하는 것을 의미한다. 산양삼, 콩 및 현미의 혼합물을 송이버섯균사체로 발효시, 놀랍게도 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산 및 리놀레산이 현저히 증진되었다 (표 1, 표 2).In the present invention, 'fermentation' means fermentation using matsutake mushroom mycelium as a spawn. When a mixture of wild ginseng, soybean and brown rice was fermented with matsutake mushroom mycelium, surprisingly, ginsenosides Rd and Rc and protopanaxadiol, oleic acid and linoleic acid were significantly increased (Tables 1 and 2).
본 발명에서 송이버섯균사체는 산양삼, 콩 및 현미의 혼합물에 3~10%(v/w) 농도로 접종하여 25~30℃에서 8~12일간 발효시키는 것으로 수행될 수 있다. 가장 바람직하게는 10일간 발효한다. In the present invention, the matsutake mushroom mycelium can be performed by inoculating a mixture of wild ginseng, beans and brown rice at a concentration of 3 to 10% (v / w) and fermenting at 25 to 30 ° C for 8 to 12 days. Most preferably fermented for 10 days.
송이버섯균사체 접종량이 3%(v/w) 미만일 경우에는 발효 속도가 지연될 수 있고 10%(v/w) 초과시에는 균사체 증식 속도가 빨라 전환율이 낮을 수 있으며, 발효 온도가 25℃ 미만일 경우 발효기간이 길어져 잡균의 오염을 초래하고 30℃를 초과할 경우에는 균사체의의 생육이 저하될 수 있고, 발효 기간이 8일 미만일 경우 발효가 충분하지 않아 생리활성물질 등의 생성이 저조하게 될 수 있으며, 12일을 초과한 경우는 과발효에 의해 생리활성물질이 분해될 수 있다.If the inoculated amount of matsutake mushroom mycelium is less than 3% (v/w), the fermentation rate may be delayed, and if it exceeds 10% (v/w), the mycelium growth rate is fast, and the conversion rate may be low. If the fermentation temperature is less than 25℃, fermentation If the period is prolonged, it causes contamination of various germs, and if the temperature exceeds 30 ℃, the growth of the mycelium may be reduced. If the fermentation period is less than 8 days, fermentation is not sufficient, resulting in low production of physiologically active substances. However, if it exceeds 12 days, physiologically active substances may be decomposed due to over-fermentation.
본 발명에서 산양삼, 콩 및 현미의 혼합물은 발효 전에, 2~3배(v/v)의 물을 첨가하여 5~8시간 수화시켜 수분이 40~50% 정도 되게 조정한 후 100℃ 이상에서 30~90분 증자처리하는 것이 바람직하다. 가장 바람직하게는 121℃에서 60분 증자한다. In the present invention, the mixture of wild ginseng, soybean, and brown rice is hydrated for 5 to 8 hours by adding 2 to 3 times (v/v) of water before fermentation to adjust the moisture to about 40 to 50%, and then to 30% at 100 ° C or higher. ~90 min steaming is preferred. Most preferably, it is cooked for 60 minutes at 121°C.
본 발명에서 수화 처리 시 수분 함량이 40% 이하의 송이버섯 균사 생육이 원활하지 않으며, 수분 함량이 50% 이상의 경우 송이버섯 균사 생육뿐만 아니라 세균 등의 증식이 이루어질 수 있다. 한편, 증자 처리 시 30분 이하 처리 시 살균이 완벽하게 이루어지 않아 송이버섯 균사 이외에 세균 등의 증식에 의하여 이상발효가 진행될 수 있고 90분 이상 처리 시 영양성분 파괴되는 과다하게 진행될 수 있다.In the present invention, during the hydration treatment, the growth of matsutake mushroom mycelia with a moisture content of 40% or less is not smooth, and when the moisture content is 50% or more, not only the growth of matsutake mushroom mycelia but also the growth of bacteria can be achieved. On the other hand, when the steaming treatment is performed for less than 30 minutes, sterilization is not completely performed, so abnormal fermentation may proceed due to the proliferation of bacteria in addition to matsutake mushroom hyphae, and when treated for more than 90 minutes, nutritional components may be destroyed excessively.
본 발명에 따른 산양삼의 송이버섯균사체 발효조성물은 진세노사이드 Rd가 2.64 mg/g 이상, 진세노사이드 Rc가 2.45 mg/g 이상 및 진세노사이드 프로토파낙사디올이 7.1 mg/g 이상, 올레산이 263 mg/100g 이상 및 리놀레산이 859 mg/100g 이상 함유한다 (표 1, 표 2). The fermented matsutake mushroom mycelium composition of wild ginseng according to the present invention has ginsenoside Rd of 2.64 mg/g or more, ginsenoside Rc of 2.45 mg/g or more and ginsenoside protopanaxadiol of 7.1 mg/g or more, oleic acid 263 mg/100 g or more and 859 mg/100 g or more of linoleic acid (Table 1, Table 2).
본 발명에 따른 산양삼의 송이버섯균사체 발효조성물은 진세노사이드 Rd, Rc 및 프로토파낙사디올의 함량이 가공전 혼합물(비교예 1)에 비하여 각각 약 6.7배 이상, 약 1.5배 이상 및 약 3.2배 이상 증진되고, 발효 전(비교예 2)에 비하여도 각각 약 3.5배 이상, 약 1.2배 이상 및 약 3.2배 이상 증진된다 (표 1). In the fermented matsutake mushroom mycelium composition of wild ginseng according to the present invention, the contents of ginsenosides Rd, Rc, and protopanaxadiol were about 6.7 times or more, about 1.5 times or more, and about 3.2 times, respectively, compared to the mixture before processing (Comparative Example 1). It is promoted more than before fermentation (Comparative Example 2) by about 3.5 times or more, about 1.2 times or more, and about 3.2 times or more, respectively (Table 1).
또한 본 발명에 따른 산양삼의 송이버섯균사체 발효조성물은 올레산 및 리놀레산의 함량이 가공전 혼합물(비교예 1) 및 발효 전(비교예 2)에 비하여 각각 약 2.1배 이상 및 약 1.8배 이상 증진된다 (표 2). In addition, in the fermented matsutake mushroom mycelium composition of wild ginseng according to the present invention, the content of oleic acid and linoleic acid is increased by about 2.1 times or more and about 1.8 times or more, respectively, compared to the mixture before processing (Comparative Example 1) and before fermentation (Comparative Example 2) ( Table 2).
또한 본 발명에 따른 산양삼의 송이버섯균사체 발효조성물은 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산, 리놀레산, 총 페놀릭스 및 총 플라보노이드스, 갈변물질 등의 생리활성물의 함량이 강화되어, 증진된 항산화 활성을 갖는다 (표 1, 표 2, 도 3a ~도 4d).In addition, the fermented matsutake mushroom mycelium composition of wild ginseng according to the present invention has enhanced content of physiologically active substances such as ginsenosides Rd, Rc, protopanaxadiol, oleic acid, linoleic acid, total phenolics and total flavonoids, and browning substances. antioxidant activity (Table 1, Table 2, Fig. 3a ~ Fig. 4d).
또한 본 발명에 따른 산양삼의 송이버섯균사체 발효조성물은 알파-글루코시다아제 저해활성과 췌장-리파아제 저해활성이 증진되어 우수한 당뇨 개선 및 비만 개선 효과를 갖는다 (도 5 및 도 6). In addition, the fermented matsutake mushroom mycelium composition of wild ginseng according to the present invention has improved alpha-glucosidase inhibitory activity and pancreatic-lipase inhibitory activity, thereby improving diabetes and obesity improvement (Figs. 5 and 6).
본 발명의 또 다른 목적을 달성하기 위하여, 본 발명은 산양삼, 콩 및 현미의 혼합물을 송이버섯균사체로 발효하여 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산, 및 리놀레산이 증진된 산양삼의 송이버섯균사체 발효조성물의 제조방법을 제공한다. In order to achieve another object of the present invention, the present invention fermented a mixture of wild ginseng, soybeans and brown rice with matsutake mushroom mycelium, and ginsenosides Rd, Rc and protopanaxadiol, oleic acid, and linoleic acid were enhanced. It provides a method for producing a mushroom mycelium fermentation composition.
구체적으로 상기 방법은 Specifically, the method
ⅰ) 산양삼 90~94 중량%, 콩 3~5 중량% 및 현미 3~5 중량%를 혼합한 후 물을 2~3배(v/w)으로 혼합하여 5~7시간 수화하는 단계;i) mixing 90-94% by weight of wild ginseng, 3-5% by weight of soybeans and 3-5% by weight of brown rice, then mixing with water 2-3 times (v / w) and hydrating for 5-7 hours;
ⅱ) 100℃ 이상에서 30 ~ 90분 증자하는 단계; 및 ii) steaming at 100°C or higher for 30 to 90 minutes; and
ⅲ) 송이버섯균사체를 3~10%(v/w) 농도로 접종하여 25~30℃에서 8~12일간 발효하는 단계를 포함한다.iii) inoculating matsutake mushroom mycelium at a concentration of 3 to 10% (v/w) and fermenting at 25 to 30 ° C for 8 to 12 days.
본 발명의 제조방법에서, 산양삼, 콩 및 현미의 혼합물의 중량비, 수화, 증자, 송이버섯균사체 및 발효는 상기에서 정의된 바와 같다. In the manufacturing method of the present invention, the weight ratio, hydration, steaming, matsutake mushroom mycelium and fermentation of the mixture of wild ginseng, soybean and brown rice are as defined above.
송이버섯균사체 원활한 발효를 위하여 발효 전에 산양삼, 콩 및 현미의 혼합물에 물을 첨가하여 수화할 수 있다.For smooth fermentation of matsutake mushroom mycelium, water can be added to the mixture of wild ginseng, soybean and brown rice before fermentation to hydrate it.
발효 전에, 살균하기 위하여 증자 처리될 수 있다. 증자는 100℃ 이상에서 30 ~ 90분 증자하는 것이 바람직하고, 가장 바람직하게는 121℃에서 60분 증자한다. Prior to fermentation, it may be steamed to sterilize. It is preferable to steam for 30 to 90 minutes at 100 ° C or higher, and most preferably for 60 minutes at 121 ° C.
본 발명의 또 다른 목적에 따라서, 본 발명은 상기 제조방법에 의해 제조된 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산, 및 리놀레산이 증진된 산양삼 송이버섯균사체 발효조성물을 포함하는 기능성식품을 제공한다. According to another object of the present invention, the present invention is a functional food comprising a fermented wild ginseng matsutake mushroom mycelium composition with enhanced ginsenosides Rd, Rc and protopanaxadiol, oleic acid, and linoleic acid prepared by the above production method to provide.
본 발명에 따른 기능성 식품은 우수한 항산화 활성, 당뇨 개선 및 비만 개선 효과를 갖는다 (도 4a~도 6). The functional food according to the present invention has excellent antioxidant activity, diabetes and obesity improvement effects (Figs. 4a to 6).
본 발명의 또 다른 목적에 따라서, 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산, 및 리놀레산이 증진된 산양삼 송이버섯균사체 발효조성물을 포함하는 화장품을 제공한다.According to another object of the present invention, to provide a cosmetic comprising a fermented wild ginseng matsutake mushroom mycelium composition with enhanced ginsenosides Rd, Rc, protopanaxadiol, oleic acid, and linoleic acid.
본 발명의 식품 또는 화장품은 본 발명의 발효조성물 또는 이의 추출물을 그대로 첨가하거나 다른 식품 성분과 혼합되어 제조될 수 있고, 통상적인 방법에 따라 적절하게 제조될 수 있다.The food or cosmetic of the present invention may be prepared by adding the fermented composition or an extract thereof of the present invention as it is or by mixing with other food ingredients, and may be appropriately prepared according to a conventional method.
본 발명에서 상기 식품의 종류는 특별히 제한되지 않으며, 환제, 정제, 캡슐제, 발효차, 발효식품 (김치류, 피클류 등), 발효음료 (파우치제, 드링크제 등) 등일 수 있으나, 이에 제한되지는 않는다. 화장품의 종류는 마스크팩, 스킨, 로션, 크림 등일 수 있으나, 이에 제한되지는 않는다. In the present invention, the type of food is not particularly limited, and may include pills, tablets, capsules, fermented tea, fermented foods (kimchi, pickles, etc.), fermented beverages (pouches, drinks, etc.), but is not limited thereto. don't Types of cosmetics may include mask packs, toners, lotions, creams, and the like, but are not limited thereto.
본 발명에 따른 산양삼 송이버섯균사체 발효조성물은 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산, 및 리놀레산이 고함량으로 함유되어 기능성식품 및 화장품의 소재로 사용될 수 있다.Wild ginseng matsutake mushroom mycelium fermented composition according to the present invention contains a high content of ginsenosides Rd, Rc and protopanaxadiol, oleic acid, and linoleic acid, so it can be used as a material for functional foods and cosmetics.
또한 본 발명에 따른 기능성식품 또는 화장품은 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산, 및 리놀레산의 함량이 높으며, 더불어 우수한 항산화 활성, 알파-글루코시다아제 저해활성 및 췌장-리파아제 저해활성을 가져서, 지방생성 억제효과, 체중 조절, 콜레스테롤 저하, 고지혈증 개선, 동맥경화 완화, 당뇨병 개선, 비만 개선, 혈액순환 개선, 면역력 개선, 여성 갱년기 증후군 개선용으로 유용하다. In addition, the functional food or cosmetic according to the present invention has a high content of ginsenosides Rd, Rc, protopanaxadiol, oleic acid, and linoleic acid, and has excellent antioxidant activity, alpha-glucosidase inhibitory activity, and pancreatic-lipase inhibitory activity. It is useful for inhibiting fat production, controlling weight, lowering cholesterol, improving hyperlipidemia, relieving arteriosclerosis, improving diabetes, improving obesity, improving blood circulation, improving immunity, and improving female menopausal syndrome.
도 1은 본 발명의 발효조성물의 제조 공정도의 일례이다.
도 2는 진세노사이드 HPLC 크로마토그램을 나타낸 것이다. (A)는 진세노사이드 21종 표준물질의 HPLC 크로마토그램이고, (B)는 비교예 1의 진세노사이드 HPLC 크로마토그램이며, (C)는 비교예 2의 진세노사이드 HPLC 크로마토그램이며, (D)는 본 발명에 따른 발효조성물의 진세노사이드 HPLC 크로마토그램이다.
도 3a는 본 발명에 따른 발효조성물의 총 페놀릭스 함량을 나타낸 것이다.
도 3b는 본 발명에 따른 발효조성물의 총 플라보노이드 함량을 나타낸 것이다.
도 3c는 본 발명에 따른 발효조성물의 갈변물질의 함량을 나타낸 것이다.
도 4는 본 발명에 따른 발효조성물의 항산화 활성을 나타내 것이다. 도 4a는 DPPH 라디칼 소거활성을, 도 4b는 ABTS 라디칼 소거활성, 도 4c는 하이드록실 라디칼 소거활성, 및 도 4d는 환원력(FRAP)을 나타낸 것이다.
도 5는 본 발명에 따른 발효조성물의 알파-글루코시다아제 저해활성을 나타낸 것이다.
도 6은 본 발명에 따른 발효조성물의 췌장-리파아제 저해활성을 나타낸 것이다.1 is an example of a manufacturing process diagram of the fermentation composition of the present invention.
Figure 2 shows a ginsenoside HPLC chromatogram. (A) is an HPLC chromatogram of 21 ginsenoside standard materials, (B) is a ginsenoside HPLC chromatogram of Comparative Example 1, (C) is a ginsenoside HPLC chromatogram of Comparative Example 2, ( D) is a ginsenoside HPLC chromatogram of the fermented composition according to the present invention.
Figure 3a shows the total phenolics content of the fermentation composition according to the present invention.
Figure 3b shows the total flavonoid content of the fermented composition according to the present invention.
Figure 3c shows the content of the browning material of the fermentation composition according to the present invention.
Figure 4 will show the antioxidant activity of the fermented composition according to the present invention. 4A shows DPPH radical scavenging activity, FIG. 4B shows ABTS radical scavenging activity, FIG. 4C shows hydroxyl radical scavenging activity, and FIG. 4D shows reducing power (FRAP).
Figure 5 shows the alpha-glucosidase inhibitory activity of the fermented composition according to the present invention.
Figure 6 shows the pancreatic-lipase inhibitory activity of the fermented composition according to the present invention.
다음의 실시예들에 의해 본 발명이 더 상세히 설명된다. 이들 실시예는 본 발명을 예시하기 위한 것이며, 본 발명의 범위가 이들에 의해 제한되어서는 안된다.The present invention is explained in more detail by the following examples. These examples are intended to illustrate the present invention, and the scope of the present invention should not be limited thereto.
제조예 1: 발효조성물 제조Preparation Example 1: Preparation of fermentation composition
산양삼은 2020년도 함양군 백전면 일대에서 재배된 것을 농업회사법인 주식회사 진생바이로으로부터 공급받아 사용하였다. 콩(오리알태콩)과 현미는 진주시 소재 대형마트에서 구입하여 사용하였다.Wild ginseng grown in Baekjeon-myeon, Hamyang-gun in 2020 was supplied and used by Ginseng Viro Co., Ltd., an agricultural corporation. Beans (duck roe beans) and brown rice were purchased from a large mart in Jinju City and used.
송이버섯 균사체는 경상대학교 임산공학과 목질화학연구실에 보관되어 있던 것을 분양받아 사용하였다. 송이버섯 균사체 계대 배양은 Potato Dextrose broth/agar(PDB/PDA, BD-Difco사, Sparks, MD, USA)를 사용하였다.Matsutake mushroom mycelium was stored in the Wood Chemistry Laboratory, Department of Forestry Engineering, Gyeongsang National University, and was used. Potato Dextrose broth/agar (PDB/PDA, BD-Difco, Sparks, MD, USA) was used for subculture of matsutake mycelium.
산양삼은 흐르는 물에 3회 세척한 후 약 1 cm 정도로 절단한 후 55℃에서 3일간 건조하여 준비하였다. 건조 산양삼과 콩, 현미를 90:5:5의 중량비로 혼합하여 산양삼 혼합시료를 준비하였다.Wild ginseng was prepared by washing three times in running water, cutting to about 1 cm, and then drying at 55 ° C for 3 days. A mixed sample of wild ginseng was prepared by mixing dried wild ginseng, beans, and brown rice at a weight ratio of 90:5:5.
산양삼 혼합시료에 2배(v/w) 정제수를 첨가하고 6시간 수화시켜 수분 함량을 약 40% 정도 되게 조정한 후 고압멸균기를 이용하여 121℃에서 1시간 동안 증자 처리하고 송이버섯 균사체 배양액을 5%(v/w) 접종한 뒤 25℃에서 10일간 발효를 진행하여 발효조성물을 얻었다 (실시예 1; 도 1). After adding 2 times (v/w) purified water to the wild ginseng mixed sample and hydrating it for 6 hours to adjust the moisture content to about 40%, it was steamed at 121℃ for 1 hour using a high-pressure sterilizer, and the matsutake mushroom mycelium culture medium was 5 After % (v/w) inoculation, fermentation was performed at 25° C. for 10 days to obtain a fermentation composition (Example 1; FIG. 1).
비교를 위하여, 건조 산양삼과 콩, 현미를 9:0.5:0.5의 중량비로 혼합하여 산양삼 혼합시료 조성물(비교예 1), 산양삼 혼합시료에 2배(v/v) 정제수를 첨가하고 6시간 수화시켜 수분 함량을 약 40% 정도 되게 조정한 후 121℃에서 1시간 동안 증자 처리한 증자시료 조성물(비교예 2)을 준비하였다.For comparison, dried wild ginseng, soybean, and brown rice were mixed at a weight ratio of 9:0.5:0.5, and 2 times (v/v) purified water was added to the mixed wild ginseng sample composition (Comparative Example 1) and the mixed wild ginseng sample, and hydrated for 6 hours. After adjusting the moisture content to about 40%, a steamed sample composition (Comparative Example 2) was prepared by steaming at 121 ° C. for 1 hour.
참조예: 분석시료Reference example: analysis sample
실시예 1의 발효조성물, 비교예 1의 조성물, 비교예 2의 조성물을 각각 55℃에서 3일간 건조하여 분쇄시켜 분말 시료를 준비하였다. Powder samples were prepared by drying the fermented composition of Example 1, the composition of Comparative Example 1, and the composition of Comparative Example 2 at 55 ° C. for 3 days, respectively, and then pulverizing them.
분말 시료 1 g에 50% 메탄올을 20배 첨가하여 12시간 동안 추출한 완전히 농축한 후 50% 메탄올을 2 ml을 첨가하여 녹인 후 0.45 ㎛ 여과 필터로 여과하여 HPLC 베일에 담아 진세노사이드를 분석하였다. 50% methanol was added to 1 g of the
분말 시료 10 g에 50% 주정을 20배 첨가하여 12시간 동안 추출한 일부 0.45 ㎛ 여과 필터로 여과하여 총 페놀릭스와 총 플라보노이드 분석에 사용하였고 나머지 추출액은 감압여과기를 이용해 여과하고 감압농축기를 이용하여 완전 농축시킨 후 동결건조기(FD-1000, Tokyo, Rikakikai, Japan)를 이용하여 동결건조하였다. 최종 동결건조된 시료에 50% 주정을 첨가하여 시료농도가 0.25, 0.5, 1.0 및 2.0 mg/ml이 되게 제조한 후 하기 생리활성시험에 사용하였다.50% alcohol was added 20 times to 10 g of the powder sample, extracted for 12 hours, filtered through a 0.45 ㎛ filtration filter, and used for analysis of total phenolics and total flavonoids. The remaining extract was filtered using a vacuum filter and completely purified using a vacuum concentrator. After concentration, it was freeze-dried using a freeze dryer (FD-1000, Tokyo, Rikakikai, Japan). 50% alcohol was added to the final freeze-dried sample to prepare sample concentrations of 0.25, 0.5, 1.0 and 2.0 mg/ml, and then used in the following physiological activity test.
시험예 1: 진세노사이드 함량 분석Test Example 1: Analysis of ginsenoside content
진세노사이드 분석은 기능성식품분석법의 홍삼 사포닌 분석법에 기술된 방법을 변형하여 고압액체크로마토그래피(HPLC, high press liquid chromatograph)로 분석하였다. 분석 컬럼은 TSKgel ODS-100Z을 사용하여 시료주입량 10 ㎕, 온도는 30℃, 측정파장은 203 nm, 유속은 1.0 ㎖/min으로 하였고 이동상으로는 A용액은 HPLC water, B용액은 아세토니트릴을 사용하였다. HPLC 분석 조건은 이동상 용액은 0분때 A용액 81% : B용액 19%로 흘려주고 15분때에는 A용액 80% : B용액 20%로 흘려주고 40분때 A용액 77% : B용액 23%, 40분때 A용액 77% : B용액 23%, 42분때 A용액 70% : B용액 30%, 75분때에 A용액 65% : B용액 35%, 80분때에 A용액 30% : B용액 70%, 90분때에 A용액 10% : B용액 90%로 이동상을 흘려주었다. 실시예 1, 비교예 1 및 비교예 2의 진세노사이드 HPLC 크로마토그램을 도 2에 나타냈고, 분석된 진세노사이드 Rd, Rc 및 프로토파낙사디올 함량을 표 1에 나타내었다.Ginsenoside analysis was analyzed by high pressure liquid chromatography (HPLC) by modifying the method described in the functional food analysis method for red ginseng saponin analysis. The analysis column was TSKgel ODS-100Z, and the sample injection amount was 10 μl, the temperature was 30 ° C, the measurement wavelength was 203 nm, and the flow rate was 1.0 ml / min. As the mobile phase, HPLC water was used as solution A and acetonitrile was used as solution B. . The HPLC analysis conditions are: 81% of A solution: 19% of B solution at 0 minutes, 80% of A solution: 20% of B solution at 15 minutes, 77% of A solution at 40 minutes: 23% of B solution at 40 minutes 77% of solution A: 23% of solution B, 42 minutes 70% of solution A: 30% of solution B, 65% of solution A at 75 minutes: 35% of solution B, 30% of solution A at 80 minutes: 70% of solution B, 90 minutes The mobile phase was flowed with A
도 2에 나타낸 바와 같이, 비교예 1 및 비교예 2의 조성물에서는 진세노사이드 Rd 피크(14), Rc 피크(10) 및 프로토파낙사디올 피크(21)이 낮게 나타난 반면에, 본 발명에 따른 실시예 1의 발효조성물에서는 진세노사이드 Rd 피크(14), Rc 피크(10) 및 프로토파낙사디올 피크(21)가 현저히 높아진 것을 확인할 수 있다. As shown in Figure 2, the compositions of Comparative Examples 1 and 2 showed low ginsenoside Rd peaks (14), Rc peaks (10) and protopanaxadiol peaks (21), whereas according to the present invention In the fermented composition of Example 1, it can be seen that the ginsenoside Rd peak (14), the Rc peak (10), and the protopanaxadiol peak (21) are significantly increased.
또한, 표 1에 나타낸 바와 같이, 실시예 1의 발효조성물은 진세노사이드 Rd가 2.64±0.13 mg/g, 진세노사이드 Rc가 2.45±0.12 mg/g, 및 진세노사이드 프로토파낙사디올이 7.10±0.36 mg/g으로 나타나, 가공되지 않은 산양산 혼합원료인 비교예 1(0.39±0.02 mg/g, 1.55±0.0.8 mg/g, 2.16±0.11 mg/g)에 비하여 각각 약 6.7배 이상, 약 1.5배 이상 및 약 3.2배 이상 증진되었고, 비교예 2 (0.74±0.04 mg/g, 2.07±0.10 mg/g, 3.15±0.16mg/g)에 비하여도 각각 약 3.5배 이상, 약 1.2배 이상 및 약 2.2배 이상 증진되었음을 확인할 수 있다.In addition, as shown in Table 1, the fermented composition of Example 1 had ginsenoside Rd of 2.64±0.13 mg/g, ginsenoside Rc of 2.45±0.12 mg/g, and ginsenoside protopanaxadiol of 7.10. ± 0.36 mg / g, respectively, about 6.7 times or more compared to Comparative Example 1 (0.39 ± 0.02 mg / g, 1.55 ± 0.0.8 mg / g, 2.16 ± 0.11 mg / g), which is an unprocessed mixed raw material from goat production. . It can be confirmed that the above and about 2.2 times or more were enhanced.
따라서 송이버섯균사체 발효된 본 발명에 따른 산양삼 발효조성물은 진세노사이드 Rd, Rc 및 프로토파낙사디올의 함량이 현저히 강화됨을 알 수 있다. Therefore, it can be seen that the fermented wild ginseng composition according to the present invention fermented with matsutake mushroom mycelium has significantly enhanced contents of ginsenosides Rd, Rc and protopanaxadiol.
시험예 2: 불포화지방산 함량 분석Test Example 2: Analysis of unsaturated fatty acid content
불포화지방산 (올레산, 리놀레산) 분석은 Hwang 등이 보고한 지방산 분석방법에 따라 수행하였다. 제조예에서 준비된 실시예 1, 비교예 1 및 비교예 2의 조성물 각각 1 g을 시험관에 정확히 칭량하고 여기에 0.5 N 메탄올성 NaOH 3 ml를 첨가하여 100℃에서 10분간 열처리하여 지방산과 글리세롤 가수분해 과정을 수행하였다. 이후 삼불화붕소(BF3) 2 ml을 추가적으로 첨가하고 교반한 후 30분간 다시 열처리하여 지방산의 메틸에스테르화를 진행하였다. 메틸에스테르화 반응 종료 후 이소옥탄 1 ml을 첨가하고 격렬히 흔든 후 방치시켜 이소옥탄층만을 회수하여 무수황산나트륨과 함께 탈수한 뒤 0.45 ㎛-막 필터로 여과하여 GC(질소 및 수소 가스와 SP-2560 capillary column (100 m×0.25 mm i.d., 0.25-μm film thickness, Sigma-Aldrich Co., St. Louis, MO, USA)로 분석하였다. 분석결과를 표 2에 나타냈다. Analysis of unsaturated fatty acids (oleic acid, linoleic acid) was performed according to the fatty acid analysis method reported by Hwang et al. 1 g of each of the compositions of Example 1, Comparative Example 1, and Comparative Example 2 prepared in Preparation Example was accurately weighed in a test tube, 3 ml of 0.5 N methanolic NaOH was added thereto, and heat treatment was performed at 100 ° C. for 10 minutes to hydrolyze fatty acids and glycerol process was performed. Thereafter, 2 ml of boron trifluoride (BF 3 ) was additionally added, stirred, and heat-treated again for 30 minutes to proceed with methyl esterification of fatty acids. After completion of the methyl esterification reaction, 1 ml of isooctane was added, shaken vigorously, and allowed to stand to recover only the isooctane layer, which was then dehydrated with anhydrous sodium sulfate, filtered through a 0.45 μm-membrane filter, and GC (nitrogen and hydrogen gas and SP-2560 capillary column ( 100 m×0.25 mm id, 0.25-μm film thickness, Sigma-Aldrich Co., St. Louis, MO, USA) The analysis results are shown in Table 2.
불포화지방산인 올레산 및 리놀레산 함량은 비교예 1 및 비교예 2의 조성물이 동일하게 124.4±6.22 mg/100g 및 466.0±23.30 mg/100g 으로, 증자 처리에 의해서는 불포화지방산의 함량이 증진되지 않는다는 것을 확인할 수 있다. The contents of oleic acid and linoleic acid, which are unsaturated fatty acids, were 124.4 ± 6.22 mg / 100g and 466.0 ± 23.30 mg / 100g, respectively, in the compositions of Comparative Example 1 and Comparative Example 2, confirming that the content of unsaturated fatty acids was not increased by the steaming treatment. can
이에 비하여, 실시예 1의 발효조성물의 올레산 및 리놀레산의 함량은 각각 263.4±13.17 mg/100g 및 859.3±42.97 mg/100g으로 나타나, 비교예 1 및 비교예 2에 비하여 각각 약 2.1배 및 약 1.8배 이상 증진되었음을 확인할 수 있다.In contrast, the contents of oleic acid and linoleic acid in the fermentation composition of Example 1 were 263.4 ± 13.17 mg / 100 g and 859.3 ± 42.97 mg / 100 g, respectively, about 2.1 times and about 1.8 times compared to Comparative Examples 1 and 2, respectively. It can be confirmed that it has been enhanced.
시험예 3. 생리활성성분 함량 분석Test Example 3. Analysis of bioactive component content
항산화 활성 등을 나타내는 생리활성성분인 총 페놀릭스, 총 플라보노이드스 함량 및 갈변물질 함량을 분석하였다.Total phenolics, total flavonoids content, and browning material content, which are physiologically active components showing antioxidant activity, were analyzed.
<총 페놀릭스 함량><Total phenolic content>
분석시료를 시험관에 0.5 ml 분주하고 여기에 25% Na2CO3 용액 0.5 ml를 첨가하여 3분간 정치시킨 후, 2N Folin-Ciocalteu 페놀 시약 0.25 ml를 첨가하여 혼합한 다음 30℃에서 1시간 동안 정치시킨 후 750 nm에서 분광광도계를 사용하여 750nm에서 흡광도를 측정하였다. 이때 총 페놀릭스 함량은 갈산(Gallic acid)을 이용하여 작성한 표준곡선으로부터 함량을 구하여 갈산에 상당하는 양으로 계산하였고 그 결과를 도 3a에 나타냈다.0.5 ml of the analysis sample was dispensed into a test tube, 0.5 ml of a 25% Na 2 CO 3 solution was added thereto, allowed to stand for 3 minutes, 0.25 ml of 2N Folin-Ciocalteu phenol reagent was added, mixed, and allowed to stand at 30°C for 1 hour. After that, absorbance was measured at 750 nm using a spectrophotometer. At this time, the total phenolic content was calculated as the amount corresponding to gallic acid by obtaining the content from the standard curve prepared using gallic acid, and the result is shown in FIG. 3a.
도 3a에 나타낸 바와 같이, 총 페놀릭스 함량은 비교예 1 및 비교예 2에서는 각각 3,26 및 4.88 mg/g이었으며, 실시예 1에서는 5.56 mg/g으로 나타나, 본 발명에 따른 발효조성물은 총 페놀릭스 함량이 증진됨을 확인할 수 있다. As shown in Figure 3a, the total phenolics content was 3,26 and 4.88 mg / g in Comparative Example 1 and Comparative Example 2, respectively, and 5.56 mg / g in Example 1, the fermentation composition according to the present invention It can be confirmed that the phenolics content is increased.
<총 플라보노이드스 함량><Total flavonoid content>
분석시료 0.5 ml에 디에틸렌글리콜 1.0 ml를 분주한 후 1 N NaOH 0.01 ml를 첨가한 후 하여 37℃ 항온수조에서 1시간 방치 후 420 nm에서 분광광도계로 흡광도를 측정하였다. 이때 총 플라보노이드스 함량은 루틴(rutin)을 이용하여 작성한 표준곡선으로부터 함량을 구하였고 그 결과는 도 3b에 나타내었다. After dispensing 1.0 ml of diethylene glycol to 0.5 ml of the analysis sample, 0.01 ml of 1 N NaOH was added, and the mixture was left in a constant temperature water bath at 37° C. for 1 hour, and then the absorbance was measured with a spectrophotometer at 420 nm. At this time, the content of total flavonoids was obtained from a standard curve prepared using rutin, and the results are shown in FIG. 3B.
도 3b에 나타낸 바와 같이, 총 플라보노이드스 함량도, 비교예 1, 비교예 2 및 실시예 1에서 각각 0.35, 0.86 및 1.30 mg/g으로 나타나, 본 발명에 따른 발효조성물은 총 플라보노이드스의 함량도 크게 증가하는 것을 확인할 수 있다.As shown in FIG. 3B, the total flavonoid content was 0.35, 0.86 and 1.30 mg/g in Comparative Example 1, Comparative Example 2 and Example 1, respectively. A significant increase can be seen.
<갈변물질 함량><Content of browning substances>
갈변물질 측정은 비효소적 갈변측정법을 이용하여 측정하였다. 분말 시료 1 g에 3차 증류수 10배 첨가한 후 1시간 동안 추출한 후 0.45 ㎛ 여과 필터로 여과한 후 여과액 1 ml 취하여 420 nm에서 분광광도계로 흡광도를 측정하여 그 결과를 도 3c에 나타내었다. Browning substances were measured using a non-enzymatic browning method. After adding 10 times of tertiary distilled water to 1 g of the powder sample, extracting for 1 hour, filtering with a 0.45 μm filtration filter, taking 1 ml of the filtrate, measuring the absorbance at 420 nm with a spectrophotometer, and the results are shown in FIG. 3C.
도 3c에 나타낸 바와 같이, 갈변물질 함량도, 비교예 1, 비교예 2 및 실시예 1에서 0.385, 0.893, 및 2.240 OD420 nm으로 나타나, 본 발명에 따른 발효조성물은 갈변물질의 함량도 크게 증가하는 것을 확인할 수 있다.As shown in Figure 3c, the browning material content, Comparative Example 1, Comparative Example 2, and Example 1, 0.385, 0.893, and 2.240 OD 420 nm , the fermentation composition according to the present invention also significantly increased the content of browning material can confirm that
시험예 4. 항산화 활성 분석Test Example 4. Antioxidant activity analysis
항산화 활성은 DPPH 라디칼 소거활성, ABTS 라디칼 소거활성, 하이드록실 라디칼 소거활성 및 FRAP 환원력을 측정하여 분석하였다.Antioxidant activity was analyzed by measuring DPPH radical scavenging activity, ABTS radical scavenging activity, hydroxyl radical scavenging activity and FRAP reducing power.
참고예에서와 같이 실시예 1, 비교예 1 및 비교예 2의 분석시료를 0.25, 0.5, 1, 2 mg/ml 농도로 제조하여 사용하였다.As in the Reference Example, the analysis samples of Example 1, Comparative Example 1, and Comparative Example 2 were prepared and used at concentrations of 0.25, 0.5, 1, and 2 mg/ml.
<DPPH 라디칼 소거활성><DPPH radical scavenging activity>
각각의 시료 0.2 ml에 DPPH 메탄올 용액(1.5×10-4 M) 0.8 ml를 첨가하여 10초간 교반후 암실에서 30분간 방치한 후 525 nm에서 흡광도를 측정하여 수행하였다. DPPH 라디칼 소거활성의 음성 대조구는 시료 대신 추출용매를 사용하여 동일한 방법으로 진행하여 흡광도의 차이를 다음과 같은 식에 의해 백분율(%)로 산출하였으며, 그 결과를 도 4a에 도시하였다. 0.8 ml of DPPH methanol solution (1.5×10 -4 M) was added to 0.2 ml of each sample, stirred for 10 seconds, left in the dark for 30 minutes, and then absorbance was measured at 525 nm. The negative control of DPPH radical scavenging activity was performed in the same manner using an extraction solvent instead of the sample, and the difference in absorbance was calculated as a percentage (%) by the following equation, and the results are shown in FIG. 4a.
라디칼 소거활성(%) = [1-(음성대조구 흡광도 ÷실험구 흡광도)] ×100Radical scavenging activity (%) = [1-(negative control absorbance ÷ test absorbance)] × 100
도 4a에 나타난 바와 같이, DPPH 라디칼 소거활성은 1 mg/ml의 농도에서 비교예 1, 비교예 2 및 실시예 2는 각각 16.67%, 49.76% 및 54.41%의 활성을 나타내 실시예 1의 발효조성물이 가장 높은 활성을 보였다. As shown in Figure 4a, the DPPH radical scavenging activity was 16.67%, 49.76%, and 54.41% of Comparative Example 1, Comparative Example 2, and Example 2, respectively, at a concentration of 1 mg/ml. showed the highest activity.
<ABTS 라디칼 소거활성><ABTS radical scavenging activity>
7 mM ABTS+와 2.45 mM K2S2O8를 1:1 비율로 섞어 암실에서 12∼16시간 반응시킨 후 메탄올과 1:88 비율로 섞어 732 nm에서 대조구의 흡광도 값이 0.7±0.02가 되도록 조절한 ABTS+ 용액을 사용하였다. 각각의 시료 0.1 ml와 ABTS+ 용액 0.9 ml를 첨가하여 혼합한 후 3분간 정치 후 즉시 732 nm에서 분광광도계를 사용하여 흡광도를 측정하였다. 음성대조구 실험은 시료 대신에 추출용매를 취하여 진행하였으며 실험구와 음성 대조구의 흡광도를 구하여 상기 식에 의해 백분율(%)로 산출하여 그 결과를 도 4b에 나타냈다.
도 4b에 나타난 바와 같이, ABTS 라디칼 소거활성은 0.5 mg/ml의 농도에서 비교예 1, 비교예 2 및 실시예 2는 각각 26.22%, 39.13% 및 47.60%의 활성을 나타내 실시예 1의 발효조성물이 가장 높은 활성을 보였다.As shown in FIG. 4B, the ABTS radical scavenging activity was 26.22%, 39.13%, and 47.60% in Comparative Example 1, Comparative Example 2, and Example 2, respectively, at a concentration of 0.5 mg/ml. showed the highest activity.
<하이드록실 라디칼 소거활성> <Hydroxyl radical scavenging activity>
각각의 시료를 1.4 ml에 10 mM FeSO4·7H2O-EDTA 0.2 ml, 10 mM 2-데옥시리보스 0.2 ml 및 10 mM H2O2 0.2 ml를 시험관에 분주하고 37℃에서 4시간 반응시켰다. 1% TBA와 2.8% TCA 1 ml을 첨가하고 100℃에서 20분간 발색한 후 520 nm 파장에서 흡과도를 측정하였다. 음성대조구는 시료대신 PBS 완충용액을 사용하여 실험하였으며 실험구와 음성대조구의 흡광도를 구하여 상기 식에 의해 백분율(%)로 산출하여 그 결과를 도 4c에 나타냈다. 0.2 ml of 10 mM FeSO 4 7H 2 O-EDTA, 0.2 ml of 10 mM 2-deoxyribose, and 0.2 ml of 10 mM H 2 O 2 were dispensed into 1.4 ml of each sample into a test tube and reacted at 37°C for 4 hours. . After adding 1 ml of 1% TBA and 2.8% TCA and developing color at 100° C. for 20 minutes, absorbance was measured at a wavelength of 520 nm. The negative control group was tested using a PBS buffer solution instead of the sample, and the absorbance of the experimental group and the negative control group was obtained and calculated as a percentage (%) by the above formula, and the result is shown in FIG. 4c.
도 4c에 나타난 바와 같이, 하이드록실 라디칼 소거활성은 1 mg/ml의 농도에서 비교예 1, 비교예 2 및 실시예 2는 각각 35.57%, 45.36% 및 50.38%의 활성을 나타내 실시예 1의 발효조성물이 가장 높은 활성을 보였다. As shown in Figure 4c, the hydroxyl radical scavenging activity of Comparative Example 1, Comparative Example 2, and Example 2 at a concentration of 1 mg/ml showed 35.57%, 45.36%, and 50.38% of the activity, respectively. The composition showed the highest activity.
<FRAP 환원력 분석><FRAP reducing power analysis>
FRAP 환원력 분석에서 반응액으로는 30 mM 아세테이트 완충액(pH 3.6), 40 mM 염산에 녹인 10 mM 2,4,6-트리피리딜-s-트리아진(TPTZ, T1253, C18H12N6, MW312.33) 및 20 mM FeCl3(F7134, MW 162.20, in DW)를 준비하였으며, 아세테이트 완충액, TPTZ 용액 및 FeCl3 용액을 10:1:1 (v/v/v)로 혼합하여 37 ℃에서 15분간 예비반응을 시켜두었다. 각각의 시료 0.05 ml에 FRAP 시약 0.95ml를 첨가하여 37 ℃에서 약 15분간 반응시키고 590 nm에서 흡광도를 측정하여 그 결과를 도 4d에 나타냈다.In the FRAP reducing power assay, the reaction solution was 30 mM acetate buffer (pH 3.6), 10
도 4d에 나타난 바와 같이, FRAP 환원력은 1 mg/ml의 농도에서 실시예 1은 1.029 OD593 nm의 가장 높은 활성을 보였다. As shown in FIG. 4d, the FRAP reducing power of Example 1 at a concentration of 1 mg/ml showed the highest activity of 1.029 OD 593 nm .
이들 결과로부터 본 발명에 따른 발효조성물은 항산화 활성이 현저히 증진됨을 알 수 있다.From these results, it can be seen that the antioxidant activity of the fermented composition according to the present invention is significantly enhanced.
시험예 5: 소화효소 저해활성 검정Test Example 5: Digestive enzyme inhibitory activity assay
본 발명에 따른 산양삼의 송이버섯사체 발효조성물에 대해 항당뇨(당뇨 개선) 효과의 지표인 알파-글루코시다아제 저해활성을 검정하였고, 항비만(비만 개선) 지표인 췌장 리파아제 저해활성을 검정하였다.Alpha-glucosidase inhibitory activity, which is an indicator of antidiabetic (diabetic improvement) effect, was assayed for the fermented matsutake mushroom carcass composition of wild ginseng according to the present invention, and pancreatic lipase inhibitory activity, which is an anti-obesity (obesity improvement) index, was assayed.
<알파-글루코시다아제 저해활성><Alpha-glucosidase inhibitory activity>
분석시료 30 ㎕에 알파-글루코시다아제 (0.5 U/ml) 효소용액 70 ㎕, 200 mM 인산나트륨 완충용액(pH 6.8) 50 ㎕를 혼합하여 37℃에서 10분간 예비반응하였다. 이후 인산나트륨 완충용액(pH 6.8)에 녹인 p-NPG (10 mM) 100 ㎕를 첨가하여 다시 37℃에서 10분 반응시켰으며 반응액에 Na2CO3 (100 mM) 750 ㎕를 첨가해 반응을 정지시킨 후 420 nm에서 분광광도계를 이용하여 흡광도를 측정하였다. 음성대조구는 시료 대신에 추출용매를 취하였으며 분석시료 첨가구와 무첨가구 사이의 흡광도 차이를 백분율(%)로 나타내어 그 결과를 도 5에 나타냈다.70 μl of alpha-glucosidase (0.5 U/ml) enzyme solution and 50 μl of 200 mM sodium phosphate buffer solution (pH 6.8) were mixed with 30 μl of the analysis sample, followed by a preliminary reaction at 37° C. for 10 minutes. Thereafter, 100 μl of p-NPG (10 mM) dissolved in sodium phosphate buffer (pH 6.8) was added and reacted at 37° C. for 10 minutes, and 750 μl of Na 2 CO 3 (100 mM) was added to the reaction solution to After stopping, absorbance was measured using a spectrophotometer at 420 nm. The negative control group took the extraction solvent instead of the sample, and the difference in absorbance between the analysis sample added and unadded was expressed as a percentage (%), and the results are shown in FIG. 5.
도 5에 도시된 바와 같이, 알파-글루코시다아제 저해활성은 2.0 mg/ml 처리 시 비교예 1에서 14.142%로 나타났으나, 실시예 1에서는 32.83 %로 증진되었다.As shown in FIG. 5, alpha-glucosidase inhibitory activity was 14.142% in Comparative Example 1 when treated with 2.0 mg/ml, but increased to 32.83% in Example 1.
따라서 본 발명에 따른 발효조성물은 알파-글루코시다아제 저해활성이 현저히 증진되어 혈당저하 활성이 우수하여 당뇨 개선효과가 증진됨을 알 수 있다.Therefore, it can be seen that the fermented composition according to the present invention significantly improves the alpha-glucosidase inhibitory activity and has excellent blood sugar lowering activity, thereby enhancing the diabetic improvement effect.
<췌장-리파아제 저해활성><Pancreatic-lipase inhibitory activity>
분석시료 30 ㎕에 췌장 리파아제 (0.5 U/ml) 효소용액 70 ㎕ 및 200 mM 인산나트륨 완충용액(pH 6.8) 50 ㎕를 혼합하여 37 ℃에서 10분간 예비반응시켰다. 반응 후 인산나트륨 완충용액에 녹인 p-NPB(10 mM) 100 ㎕를 첨가하여 동일하게 10분간 반응시킨 후 100 mM Na2CO3 750 ㎕를 첨가해 반응을 종결시켜 420 nm에서 흡광도를 측정하였다. 음성대조구는 시료 대신에 추출용매를 취하였으며 시료용액의 첨가구와 무첨가구 사이의 흡광도 차이를 백분율(%)로 나타내어 그 결과를 도 6에 나타냈다.70 μl of pancreatic lipase (0.5 U/ml) enzyme solution and 50 μl of 200 mM sodium phosphate buffer (pH 6.8) were mixed with 30 μl of the analysis sample, followed by pre-reaction at 37° C. for 10 minutes. After the reaction, 100 μl of p-NPB (10 mM) dissolved in sodium phosphate buffer was added and reacted for 10 minutes in the same manner, and then the reaction was terminated by the addition of 750 μl of 100 mM Na 2 CO 3 and absorbance was measured at 420 nm. In the negative control group, an extraction solvent was taken instead of the sample, and the difference in absorbance between the added and unadded groups of the sample solution was expressed in percentage (%), and the results are shown in FIG. 6.
도 6에 도시된 바와 같이, 췌장 리파아제 저해활성은 2.0 mg/ml 처리 시 비교예 1에서 10.00%, 비교예 2에서 28.77%로 나타났으나, 실시예 1에서는 35.12%로 더 높은 활성을 보였다. As shown in FIG. 6, the pancreatic lipase inhibitory activity was 10.00% in Comparative Example 1 and 28.77% in Comparative Example 2 when treated with 2.0 mg/ml, but in Example 1, it showed a higher activity at 35.12%.
따라서 본 발명에 따른 발효조성물은 췌장 리파아제 저해활성이 증진되어 비만 개선효과가 강화됨을 알 수 있다.Therefore, it can be seen that the fermented composition according to the present invention enhances the pancreatic lipase inhibitory activity, thereby enhancing the obesity improvement effect.
상기 활성(기능성) 검정 결과들로부터, 본 발명에 따른 발효조성물은 진세노사이드 Rd, Rc 및 프로토파낙사디올, 올레산, 및 리놀레산의 함량이 증진될 뿐만 아니라, 우수한 항산화 활성, 항당뇨 및 항비만 활성을 가져서 기능성 식품 및 화장품의 소재로 유용하다는 것을 알 수 있다.From the above activity (functionality) assay results, the fermented composition according to the present invention not only improves the contents of ginsenosides Rd, Rc and protopanaxadiol, oleic acid, and linoleic acid, but also has excellent antioxidant activity, antidiabetic and antiobesity It can be seen that it has activity and is useful as a material for functional foods and cosmetics.
Claims (8)
상기 발효조성물은 진세노사이드 Rd 2.64 mg/g 이상, 진세노사이드 Rc 2.45 mg/g 이상, 진세노사이드 프로토파낙사디올 7.1 mg/g 이상, 올레산 263 mg/100g 이상 및 리놀레산 859 mg/100g 이상 함유하는 것을 특징으로 하는 발효조성물.
After mixing 2-3 times (v/w) of water with a mixture of 90-94% by weight of wild ginseng, 3-5% by weight of soybean, and 3-5% by weight of brown rice, hydrated for 5-7 hours, and heated to 100℃ or higher. After steaming for 30 to 90 minutes, matsutake mushroom mycelium was inoculated at a concentration of 3 to 10% (v/w) and fermented at 25 to 30 ° C for 10 to 12 days to produce ginsenosides Rd, Rc and protopanaxadiol. , A composition for fermenting matsutake mushroom mycelium of wild ginseng with enhanced oleic acid and linoleic acid,
The fermented composition contains ginsenoside Rd of 2.64 mg/g or more, ginsenoside Rc of 2.45 mg/g or more, ginsenoside protopanaxadiol of 7.1 mg/g or more, oleic acid of 263 mg/100g or more, and linoleic acid of 859 mg/100g or more. Fermentation composition characterized in that it contains.
A functional food for improving diabetes and obesity, comprising the fermented composition according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200135163A KR102545365B1 (en) | 2020-10-19 | 2020-10-19 | Fermentation composition of mountain-cultivated ginseng having increased ginsenoside Rd, Rc and Protopanaxadiol by using Tricholoma matsutake mycelium and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200135163A KR102545365B1 (en) | 2020-10-19 | 2020-10-19 | Fermentation composition of mountain-cultivated ginseng having increased ginsenoside Rd, Rc and Protopanaxadiol by using Tricholoma matsutake mycelium and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220051584A KR20220051584A (en) | 2022-04-26 |
KR102545365B1 true KR102545365B1 (en) | 2023-06-20 |
Family
ID=81391568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200135163A KR102545365B1 (en) | 2020-10-19 | 2020-10-19 | Fermentation composition of mountain-cultivated ginseng having increased ginsenoside Rd, Rc and Protopanaxadiol by using Tricholoma matsutake mycelium and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102545365B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102090408B1 (en) * | 2018-11-23 | 2020-04-07 | 함양군농촌마을관광협동조합 | Premixed composition for beverage containing increased ginsenoside Re, Rd2, F2 and protopanaxdiol and preparation method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101889596B1 (en) * | 2015-11-02 | 2018-08-20 | 경남과학기술대학교 산학협력단 | Composition of mixed grains fermented with Tricholoma matsutake mycelium having excellent flavor and enhanced functionality, and preparation method thereof and use thereof in food industry |
KR101993777B1 (en) * | 2016-10-26 | 2019-07-01 | 경남과학기술대학교 산학협력단 | Solid fermented soybean with mushroom and method for preparation thereof |
KR102231913B1 (en) * | 2019-04-03 | 2021-03-25 | 함양군 | Vegetable Brown Sauce having high biological active materials and preparation method thereof |
-
2020
- 2020-10-19 KR KR1020200135163A patent/KR102545365B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102090408B1 (en) * | 2018-11-23 | 2020-04-07 | 함양군농촌마을관광협동조합 | Premixed composition for beverage containing increased ginsenoside Re, Rd2, F2 and protopanaxdiol and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20220051584A (en) | 2022-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101569089B1 (en) | Method for preparing ginsenoside derivative and composition comprising ginsenoside derivative prepared by the same for whitening and improving wrinkle | |
KR102386296B1 (en) | Complex-fermented composition of Fabaton soybean leaves and Schisandra chinensis having enhanced anti-diabetic and anti-obesity effects and preparation method thereof | |
KR101965059B1 (en) | Preparation method of Fabaton soybean leaves composition having high in genistein and daidzein content and a composition having effective components to alleviate climacteric symptoms prepared by the same method | |
KR102403798B1 (en) | Fermented broth comprising ginsenoside originated the leaf of ginseng and manufacturing method thereof | |
KR101482873B1 (en) | Fermentation metabolite of Dendropanax morbiferus produced by liquid-state fermentation and manufacturaring process for the same | |
KR101963978B1 (en) | Composition of fermented sprout ginseng having increased ginsenosides Rh2 and compound K, bioactive components, and preparation method thereof | |
KR101980450B1 (en) | Composition of active wild-cultivated ginseng having increased ginsenoside Rd and compound K, chlorgenic acid and quercetin, and preparation method thereof | |
KR101963046B1 (en) | Composition of processed ginseng having increased ginsenoside compound K, chlorgenic acid and quercetin, and preparation method thereof | |
KR102133721B1 (en) | functional food composition for antioxidant effect comprising fermented permission leaf | |
KR102545365B1 (en) | Fermentation composition of mountain-cultivated ginseng having increased ginsenoside Rd, Rc and Protopanaxadiol by using Tricholoma matsutake mycelium and preparation method thereof | |
KR102001632B1 (en) | Platycodon radix composition containing high protocatechuic acid, epicatechin, and oleic acid and enhanced inhibition activities of alpha-glucosidase and pancreatic lipase, and preparation method thereof | |
KR102557683B1 (en) | Fermentation composition of sprouts of mountain-cultivated ginseng having increased ginsenoside Rg3 and Protopanaxadiol, Rutin, Chlorogenic acid and Essential amid acids by using Tricholoma matsutake mycelium and preparation method thereof | |
KR102464052B1 (en) | Composition of complex-fermented sprout ginseng having increased ginsenoside F2, Rg3, Rd2 and compound K, chlorogenic acid, coumaric acid, catechin and quercetin, and preparation method thereof | |
KR102094084B1 (en) | Aged and complex-fermented mountain-cultivated ginseng having increased ginsenosides of human body absorption type and omega-6 fatty acid, and preparation method thereof | |
KR100801435B1 (en) | Manufacturing Method of Chaga mushroom fermentation drink that have high poisonous oxygen elimination ability | |
KR102132537B1 (en) | Platycodon grandiflorum Liquid composition for stick-type container having increased ginsenosides of human body absorption type, and preparation method thereof | |
KR102364062B1 (en) | Composition for anti-inflammation containing active mountain-cultivated ginseng and preparation method thereof | |
KR20170100965A (en) | Manufacturing Method of Fermentation Liquor of Extract from Mulberry and White Ginsing | |
KR102564529B1 (en) | Fermentation composition of complex-fermented of Fabaton soybean leaves by using Tricholoma matsutake mycelium and preparation method thereof | |
KR20230064287A (en) | A Monascus fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof | |
KR20230065499A (en) | A mushroom-mycelium fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof | |
KR102482910B1 (en) | Composition of complex-fermented Fabaton soybean leaves having increased aglycon isoflavones, oleic acid and niacin, and preparation method thereof | |
KR20210067333A (en) | Method for producing fermented Beta vulgaris extract with improved antioxidant activity and fermented Beta vulgaris extract produced by the same method | |
KR102585372B1 (en) | Composition for relieving hangover containing ginseng fermented extract, Gamoderma Lucidum mycelium culture supernatant and Trametes versicolor mycelium culture supernatant as an active ingredient | |
KR20220110131A (en) | A composition of sprouts of ginseng fermented by using Tricholoma matsutake mycelium having increased veratric acid, naringenin, ginsenoside Ro and protopanaxadiol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |